Logo Image
Feature|Videos|July 3, 2024

Public Perception and Communicating the Potential and Safety of mRNA

Experts discuss the critical need for cultivating public trust as mRNA technology makes promising advancements in treating a range of diseases.

Episodes in this series

Peter Marks, MD, PhD, stresses the need for the scientific community to clarify to the public that the rapid development of COVID-19 vaccines did not compromise safety protocols. Constanze Blume, PhD, agrees, noting that healthcare professionals and authorities should educate the public on the safety and efficacy of mRNA therapies. Fouad Atouf, PhD, focuses on several aspects of public communication, including safety, efficacy, and addressing misinformation, and points out the opportunity to leverage lessons from the COVID-19 vaccines to illustrate the public health benefits of mRNA technology. Kenneth Chien, MD, PhD, highlights the broad applicability of mRNA for various diseases, while acknowledging that the technology is still in its early stages, with much work to be done until its full potential can be realized.

Discussion Topics

  • 0:00:08 - Communicating the safety and efficacy of mRNA technology to the public, addressing misinformation, and highlighting the public health benefits
  • 0:02:32 - The importance of healthcare professionals and authorities in educating the public on the opportunities and safety of mRNA therapies
  • 0:03:40 - The potential of mRNA technology, the need for further advancements, and drawing analogies to the IT sector
  • 0:05:36 - The safety and delivery of mRNA vaccines and therapeutics, and the potential for streamlining regulatory pathways for rare disease applications

Related to this article

View more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more